Scioderm, Inc., a Durham, North Carolina-based clinical-stage pharmaceutical company, raised $20m in Series B financing.
The round was led by new investor Redmile Group, with participation from current investors Morganthaler Ventures and Technology Partners. In conjunction with the funding, Mike Lee of Redmile Group will join Scioderm’s Board of Directors.
Led by Robert Ryan, Ph.D., Chief Executive Officer, Scioderm develops innovative therapies to address diseases with critical unmet medical needs, including orphan products.
The company intends to use the proceeds to fund the development of ZorblisaTM (SD-101)*, a proprietary topical therapy being developed for the treatment of all patients with Epidermolysis Bullosa (EB), through completion of the US and EU clinical registration programs. It intends to initiate the trial in the first quarter of 2015, and expects to have top-line results in the second half of 2015.
FinSMEs
19/12/2014